在HER2-表达的先进泌尿器癌中,迪西他马布维多丁加托里帕利马布
Xinan Sheng1, Gongqian Zeng2, Cuijian Zhang3
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing.
与化疗相比,disitamab vedotin加toripalimab显著改善了先前未经治疗的HER2-表达性晚期泌尿器癌患者的无进展和整体存活率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 尿路细胞癌是什么意思
背景情况:
- 针对HER2的抗体-药物结合单一疗法在晚期泌尿器癌中显示出有前途.
- 与PD-1免疫疗法相结合的迪西他马布维多丁 (一种HER2特异性ADC) 显示出抗瘤活性和安全性.
研究的目的:
- 评估在未经治疗的HER2表达局部先进或转移性泌尿器癌中,维多丁加托利帕利马布与化疗的疗效和安全性.
主要方法:
- 第三阶段,多中心,开放标签,随机试验.
- 484名患者随机分组1:1接受维多丁+托利帕利马布 (2周一次) 或化疗 (3周一次) 的迪西塔马布.
- 双重初级终点:无进展生存率 (PFS) 和整体生存率 (OS).
主要成果:
- 迪西他马布维多丁+托利帕利马布显著改善了PFS (13.1与6.5个月相比;HR 0.36) 和OS (31.5与16.9个月相比;HR 0.54).
- 使用迪西塔马布维多丁+托里帕利马布 (76.1%对比50.2%) 的客观应答率更高.
- 迪西他马布维多丁 + 托利帕利马布显示出更有利的安全性概况,较少的3级+不良事件 (55.1% vs 86.9%).
结论:
- 与化疗相比,disitamab vedotin加上toripalimab在未经治疗的HER2表达性晚期泌尿器癌中提供了更好的结果.
- 这种组合代表了这个患者群体的有前途的新治疗策略.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
